| HOME >> BIOLOGY >> TECHNOLOGY |
SAN DIEGO, Dec. 3, 2010 /PRNewswire-FirstCall/ -- Sequenom, Inc. (Nasdaq: SQNM) today announced that the underwriters of its previously announced common stock offering that priced on December 2, 2010 have exercised in full an option to purchase an additional 2,100,000 shares of its common stock. Including the additional shares being purchased, the offering will total 16,100,000 shares at a public offering price of $6.00 per share, resulting in aggregate gross proceeds to Sequenom of $96.6 million (before deducting underwriting discounts and commissions and other estimated offering expenses payable by Sequenom).
(Logo: http://photos.prnewswire.com/prnh/20040415/SQNMLOGO)
Jefferies & Company, Inc. is acting as sole book-running manager for the offering, and Lazard Capital Markets LLC and Piper Jaffray & Co. are acting as co-managers for the offering. The offering is expected to close on or about December 7, 2010, subject to customary closing conditions.
Sequenom anticipates using the net proceeds from the offering for general corporate purposes, including research and development expenses, such as expenses related to its validation studies for Trisomy 21, capital expenditures, working capital and general administrative expenses.
The securities described above are being offered by Sequenom pursuant to a shelf registration statement previously filed with the Securities and Exchange Commission (the "SEC"), which the SEC declared effective on October 5, 2010. A final prospectus supplement related to the offering has been filed with the SEC and is available on the SEC's website located at http://www.sec.gov. Copies of the final prospectus supplement relating to these securities may also be obtained from Equity Syndicate Prospe
'/>"/>
| SOURCE Sequenom, Inc. Copyright©2010 PR Newswire. All rights reserved |